U.S. market Closed. Opens in 3 hours 40 minutes

ALIM | Alimera Sciences, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 5.53 - 5.56
52 Week Range 2.6060 - 5.65
Beta 1.35
Implied Volatility 64.10%
IV Rank 1.02%
Day's Volume 2,677,974
Average Volume 866,825
Shares Outstanding 54,384,200
Market Cap 301,288,468
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
IPO Date 2019-11-04
Valuation
Profitability
Growth
Health
P/E Ratio 5.28
Forward P/E Ratio 6.94
EPS 1.05
1YR Price Target 8.00
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 154
Country USA
Website ALIM
Alimera Sciences is a pharmaceutical company focused on commercializing and developing treatments that address diseases affecting the back of the eye (retina). ILUVIEN(R) is Alimera's a patented micro-implant which delivers a continuous, low dose anti-inflammatory agent to the retina for up to 3 years. A $2B global market, DME is often treated with acute therapies when the fluid in the eye returns. ILUVIEN reduces the recurrence of edema leading to stable vision, with the benefit of continuous treatment due to the product's novel drug delivery technology.
*Chart delayed
Analyzing fundamentals for ALIM we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is on medium level and Health is very weak. For more detailed analysis please see ALIM Fundamentals page.

Watching at ALIM technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on ALIM Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙